Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary and promising approach for cancer treatment. However, its potential is limited by technical challenges and safety risks associated with viral transduction–based CAR T-cell generation workflows. Nonviral delivery methods, such as electroporation, represent a potentially safer and less challenging approach for generating CAR T cells. Flexible, high-throughput technologies such as flow cytometry can greatly assist in reducing the challenges of CAR-T workflows.
In this webinar, we describe the generation of anti-CD19 CAR T cells in an mRNA electroporation–based CAR T-cell workflow optimized for efficiency and viability.
You will learn how to:
- Optimize CAR transfection efficiencies as high as ~70 and ~90% in primary and immortalized human T cells, respectively
- Avoid the potential risks associated with viral transduction
- Demonstrate mRNA electroporation as an effective approach in CAR T-cell workflows
- Use flow cytometry in CAR T-cell therapy development
Michael Kirmiz, PhD,
Senior Scientist, Cell Biology
Dr. Michael Kirmiz is a senior scientist at Bio‑Rad in the Life Science R&D Group, where he supports the Bio-Rad catalog of cell biology instrumentation. Michael earned his PhD from the University of California, Davis, where he leveraged advanced imaging and proteomic approaches to study neuronal cell biology. He then held a postdoctoral position at Stanford University, where he developed novel molecular approaches to study cellular signaling in T cells. Michael has over 10 years of experience in cell biology and has been at Bio-Rad for 1 year.